Final Data from Open-Label Extension Studies of Dalfampridine Extended Release Tablets in Multiple Sclerosis

被引：0
|
作者：
Goodman, Andrew [1 ]
Blight, Andrew [2 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Acorda Therapeut Inc, Hawthorne, NY USA
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P04128
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated analysis of open-label extension studies of dalfampridine extended release tablets in multiple sclerosis
    Goodman, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S245 - S246
  • [2] Open-label extension patient retention rates with dalfampridine extended-release tablets in multiple sclerosis
    Schapiro, R.
    Bethoux, F.
    Brown, T.
    Williamson, L.
    Rabinowicz, A.
    Marinucci, L.
    Carrazana, E.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 477 - 477
  • [3] Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
    Okuda, Darin T.
    Kantor, Daniel
    Jaros, Mark
    de Vries, Tina
    Hunter, Samuel
    BRAIN COMMUNICATIONS, 2022, 5 (01)
  • [4] Dalfampridine Extended Release In Multiple Sclerosis
    Chwieduk, Claudine M.
    Keating, Gillian M.
    CNS DRUGS, 2010, 24 (10) : 883 - 891
  • [5] Change in Walking Speed in Transition from Double-Blind to Open Label Clinical Trials of Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis
    Goodman, Andrew D.
    NEUROLOGY, 2011, 76 (09) : A604 - A605
  • [6] Interim Analysis of Open-Label Extension Studies of Sustained Release Fampridine in Patients with Multiple Sclerosis
    Goodman, Andrew D.
    Brown, Ted R.
    Edwards, Keith R.
    Schapiro, Randall T.
    Marinucci, Lawrence N.
    Cohen, Ron
    Blight, Andrew R.
    NEUROLOGY, 2010, 74 (09) : A101 - A101
  • [7] Patients with Progressive Forms of Multiple Sclerosis Benefit from Treatment with Dalfampridine Extended Release Tablets
    Pozzilli, Carlo
    Goodman, Andrew
    NEUROLOGY, 2011, 76 (09) : A73 - A73
  • [8] Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
    Hauser, Stephen L.
    Kappos, Ludwig
    Arnold, Douglas L.
    Bar-Or, Amit
    Brochet, Bruno
    Naismith, Robert T.
    Traboulsee, Anthony
    Wolinsky, Jerry S.
    Belachew, Shibeshih
    Koendgen, Harold
    Levesque, Victoria
    Manfrini, Marianna
    Model, Fabian
    Hubeaux, Stanislas
    Mehta, Lahar
    Montalban, Xavier
    NEUROLOGY, 2020, 95 (13) : E1854 - E1867
  • [9] Interim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis
    Goodman, A. D.
    Brown, T.
    Krupp, L.
    Schapiro, R.
    Marinucci, L.
    Cohen, R.
    Blight, A.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S13 - S13
  • [10] Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 52-week, open-label extension studies
    Eerdekens, M.
    Kramer, M.
    Martinez, L.
    Lane, R.
    Lim, P.
    Canuso, C.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 429 - 429
12345